IPSC insider sale: 292 shares; 405,131 shares remain owned
Rhea-AI Filing Summary
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 292 shares
Net Sell
1 txn
Insider
Carr Douglas
Role
SVP Finance & Operations
Sold
292 shs ($171.11)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 292 | $0.586 | $171.11 |
Holdings After Transaction:
Common Stock — 405,131 shares (Direct)
Footnotes (1)
- F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Century Therapeutics (IPSC) disclose in this Form 4?
An insider sale of 292 shares of common stock at $0.586 on November 3, 2025.
Who executed the transaction at Century Therapeutics (IPSC)?
The SVP Finance & Operations, as the reporting person on the Form 4.
When did the IPSC insider transaction occur?
The transaction date was November 3, 2025.